A Study to See if we Can Predict How Your Liver Tumor or Liver Metastases Will Respond to Trans-Arterial Embolization (TAE)

Withdrawn before enrolling

Conditions studied: Liver Cancer, Liver Metastases

In brief

The purpose of this study is to see if certain genes the tumor can help predict how the tumor will respond to Trans-Arterial Embolization (TAE). A gene is the basic physical and functional unit of heredity. Genes are made up of DNA; DNA (deoxyribonucleic acid) is the hereditary material in humans. Identifying a gene that can predict how liver tumors will respond to TAE will also help to determine if adjuvant therapy will be needed after TAE.

Key facts

Study ID

NCT02772575

Run by

Memorial Sloan Kettering Cancer Center

People needed

0

Starts

2016-04-01

Last updated by the study team

2017-01-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histopathologic evidence of primary liver cancer or liver metastases
• Indication of TAE for the treatment of liver tumor
• Age ≥ 18 years
• Available tissue with adequate tissue for analysis, verified by a pathologist

You may not qualify if…

• History of a second active malignancy with evidence of metastatic disease

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.